Generali Asset Management SPA SGR Lowers Holdings in Insulet Corporation $PODD

Key Points

• Generali Asset Management SPA SGR reduced its holdings in Insulet Corporation by 45.0%, owning 2,809 shares after selling 2,299 shares in the second quarter, with a valuation of $883,000.
• Insulet Corporation reported $1.17 EPS for the quarter, surpassing estimates of $0.92, and achieved a 32.9% increase in revenue year-over-year with $649.10 million.
• Analysts have rated Insulet with a consensus of "Moderate Buy" and an average target price of $348.05, with some predictions showing potential price targets as high as $415.00.

Generali Asset Management SPA SGR trimmed its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 45.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,809 shares of the medical instruments supplier's stock after selling 2,299 shares during the quarter. Generali Asset Management SPA SGR's holdings in Insulet were worth $883,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Sequoia Financial Advisors LLC lifted its holdings in shares of Insulet by 2.3% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier's stock worth $634,000 after buying an additional 45 shares during the period. Nissay Asset Management Corp Japan ADV raised its position in shares of Insulet by 0.6% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier's stock worth $2,222,000 after acquiring an additional 48 shares in the last quarter. Mather Group LLC. raised its position in shares of Insulet by 4.4% in the 2nd quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier's stock worth $360,000 after acquiring an additional 48 shares in the last quarter. Brooklyn Investment Group raised its position in shares of Insulet by 7.0% in the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier's stock worth $209,000 after acquiring an additional 52 shares in the last quarter. Finally, Cooper Financial Group raised its position in shares of Insulet by 5.7% in the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock worth $283,000 after acquiring an additional 58 shares in the last quarter.

Insulet Trading Up 0.7%

Shares of NASDAQ:PODD opened at $318.59 on Friday. The business's 50-day moving average is $326.22 and its 200 day moving average is $301.98. Insulet Corporation has a 1 year low of $226.50 and a 1 year high of $353.50. The firm has a market capitalization of $22.43 billion, a P/E ratio of 96.84, a P/E/G ratio of 2.64 and a beta of 1.40. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. During the same period in the prior year, the company posted $0.55 EPS. The firm's quarterly revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on PODD shares. Zacks Research raised Insulet from a "hold" rating to a "strong-buy" rating in a research report on Tuesday. Oppenheimer boosted their price target on Insulet from $324.00 to $365.00 and gave the stock an "outperform" rating in a research report on Monday, September 8th. Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. JPMorgan Chase & Co. boosted their price target on Insulet from $340.00 to $415.00 and gave the stock an "overweight" rating in a research report on Friday, September 12th. Finally, Morgan Stanley reissued an "overweight" rating on shares of Insulet in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Insulet currently has a consensus rating of "Moderate Buy" and an average target price of $348.05.

Insider Transactions at Insulet

In other news, SVP Prem Singh sold 687 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by corporate insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.